BioWorld

Dec. 10, 2004

View Archived Issues

Nastech Triples Cash With Public Sale Worth $57.4M

Padding its savings account and then some, Nastech Pharmaceutical Co. Inc. raised about $57.4 million in gross proceeds through a public offering. (BioWorld Today) Read More

Dynavax's Phase II/III HBV Data Supportive; Phase III Trials Next

Read More

Putting Nobel Prize-Winning Proteasome Research To Use

Read More

With $62M Offering, Array Can Push More Into Clinic

Read More

Other News To Note

Read More